FDA Grants Priority Review for Cosentyx Supplement Application
The FDA has granted priority review for the supplemental biologics application for Cosentyx (secukinumab) submitted by Novartis.
Company
Novartis
Asset
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The FDA's grant of priority review for Cosentyx's supplemental application is significant as it may lead to expedited approval for new indications, enhancing Novartis's competitive position. Portfolio teams must prepare for potential market changes and assess impacts on existing therapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's decision timeline and any announcements regarding additional indications for Cosentyx.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.